CAMBRIDGE, Mass. - Foghorn Therapeutics Inc. (NASDAQ:FHTX), a biotechnology firm focused on developing novel medicines through gene expression correction, announced today the appointment of two ...

The 94-year-old noted that he will not sell a single share of the company. We sell different types of products and services to both investment professionals and individual investors. These ...

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious ...

Citizens JMP initiated coverage of Foghorn Therapeutics (FHTX) with an Outperform rating and $9 price target Foghorn is a clinical-stage biotechnology company focused on developing novel therapies ...

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...

CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious ...

Get Our Latest Research Report on FHTX Foghorn Therapeutics Stock Up 0.7 % FHTX opened at $4.39 on Tuesday. Foghorn Therapeutics Inc. has a 52 week low of $2.94 and a 52 week high of $10.25. The ...

CAMBRIDGE, Mass. - Foghorn Therapeutics Inc. (NASDAQ:FHTX), a biotechnology firm focused on developing novel medicines through gene expression correction, announced today the appointment of two new ...

Foghorn Therapeutics Inc. has announced the election of Dr. Neil Gallagher and Stuart Duty to its Board of Directors, aiming to enhance its strategic outlook as it advances its pipeline of novel ...

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...

(MENAFN- GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of ...